Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

License For Prolia And Xgeva Rivals Follows Ustekinumab Deal With Bio-Thera

 
• By David Wallace
  
Building A Brick Wall, Bricklayers
The next piece has fallen into place for Hikma’s US biosimilars business • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business